Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Diabetes
•
Obesity Medicine
•
General Endocrinology
•
Primary Care
Should we be using body fat percentage instead of BMI for determining patients' risk of metabolic syndrome?
https://pubmed.ncbi.nlm.nih.gov/38747476/
Related Questions
Should we be more cautious with the use of GLP 1 R agonist therapy in patients with Type 1 diabetes mellitus and obesity given the increased risk of cardiovascular disease with high body weight variability?
When and how should we be stopping GLP-1 Receptor Agonist/Dual Agonist therapy?
Can rapid weight loss following GLP1 R agonist therapy lead to postprandial hypoglycemia and if so, what are the treatment options outside of dietary modifications?
Do you recommend routinely monitoring pancreatic markers such as amylase and lipase while receiving GLP1 R agonist or dual agonist therapies to determine their risk of pancreatitis?
Do you recommend the use of Korlym (Mifepristone) for patients with difficult to control diabetes and evidence of mild endogenous hypercortisolism of unknown source?
Would you order a fibroscan to screen for MASLD in patients with insulin resistance but normal LFTs?
Do you recommend adding low-dose Aspirin for primary prevention in patients with Type 2 Diabetes on Eliquis for another indication?
Would you prescribe a GLP-1 receptor agonist for an obese patient with low to moderate cardiovascular risk but a high CAC score?
Does oral semaglutide provide similar cardiovascular risk reduction benefits as injectable semaglutide?
Is it safe to prescribe Invokana or Metformin for patients taking Biktarvy?
